Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. April 2004 07:30 ET | Quelle: Endovasc Inc.

Endovasc Announces Early Closure of Patient Recruitment for Liprostin Clinical Trial

MONTGOMERY, Texas, April 1, 2004 (PRIMEZONE) -- Endovasc Inc. (OTCBB:EVSC), a drug development company that pioneers new cardiovascular and metabolic drug therapies, announced today the completion of...
12. Februar 2004 16:00 ET | Quelle: Endovasc Inc.

Endovasc Provides Status Report on its $200 Million Case Against Alleged Stock Manipulators

MONTGOMERY, Texas , Feb. 12, 2004 (PRIMEZONE) -- Endovasc Inc. (OTCBB:EVSC), a drug development company that pioneers new cardiovascular and metabolic drug therapies, announced today an update on the...
28. Januar 2004 08:30 ET | Quelle: Endovasc Inc.

Two Clinical Sites in Mexico City Join Endovasc's Liprostin Phase II Trial

MONTGOMERY, Texas, Jan. 28, 2004 (PRIMEZONE) -- Endovasc Inc. (OTCBB:EVSC), a drug development company that pioneers new cardiovascular and metabolic drug therapies, announced today that...
22. Januar 2004 08:30 ET | Quelle: Endovasc Inc.

Endovasc Opens Four Sites in Moscow to Participate in Phase II Clinical Trial to Treat Patients Suffering from Peripheral Vascular Disease

MONTGOMERY, Texas, Jan. 22, 2004 (PRIMEZONE) -- Endovasc Inc. (OTCBB:EVSC), a drug development company that pioneers new cardiovascular and metabolic drug therapies, is pleased to announce that...